Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder ...
Background Mpox emerged as a significant global public health concern during the 2022–2023 outbreak, impacting populations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback